24AUG

Chip firm OLIX prints $312m at $3.3bn

3 min read

16:40UTC

London inference-chip company OLIX confirmed a $312m Series B at a $3.3bn valuation, and quietly hired Wise's former finance chief to run its own books.

← Back to UKRI's sponsor department no longer exists Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Olix raised $312m at $3.3bn and hired Wise's IPO-era CFO two years before first silicon ships.

Olix, a London inference-chip company founded in 2024, confirmed a $312m Series B at a $3.3bn valuation on 3 August in its own release⁠¹. Arm, Fundomo and Hudson River Trading joined, Reed Hastings came in as an angel, and every existing backer increased its commitment. Inference chips run trained AI models rather than training them, a workload that now consumes most of the compute a deployed model ever uses.

Two appointments went unreported in the trade write-ups of the round. Nick McKeown, the Stanford professor who co-invented software-defined networking and won the 2025 Marconi Prize, joined the board. Matt Briers, chief financial officer (CFO) of Wise from 2015 through its 2021 London listing, took the same job at Olix. Hiring a CFO who has already taken a British technology company through a London IPO is a specific piece of forward planning, and it lands well before Olix's DX-1 decode accelerator reaches first customers in the second half of 2027.

Olix's own release and the government's release of the same date describe the round differently. The company names its new investors and does not mention state capital; gov.uk states that Olix is the fifth company to receive equity investment from the Sovereign AI Fund since it launched⁠². A company release is a marketing document rather than a share register, and omission from one carries no information about who holds the stock. CuspAI's July round listed the investor under its other label, Sovereign AI Unit.

Deep Analysis

In plain English

Olix is a London company building a specialised computer chip, the kind used to run trained AI models quickly and cheaply, called an inference chip. This is different from the chips used to train AI models in the first place; Nvidia dominates that market, and companies like Olix are betting the market for running those models will grow even bigger. Olix raised $312m from investors, valuing the company at $3.3bn. Big names joined: Arm, the Cambridge company whose chip designs sit inside most smartphones, and Reed Hastings, the co-founder of Netflix, investing his own money rather than through a fund. Olix also hired two experienced people: a Stanford professor who helped invent a major networking technology, and the former finance chief of Wise, the money-transfer company that listed in London in 2021. The catch: Olix's actual chip, the DX-1, will not reach its first paying customers until the second half of 2027. Investors are paying a $3.3bn price today for a product that has not yet been tested by anyone outside the company.

Deep Analysis

Root Causes

Olix's valuation rests on a structural bet common to inference-chip start-ups: training chips, Nvidia's dominant market, and inference chips, running trained models cheaply at volume, are different economics, and investors are pricing the second market on the assumption that inference workload will outgrow training workload as AI models move from being built to being used.

Callosum's $100m raise six days later, covered elsewhere in this briefing, shows capital consolidating in AI infrastructure rather than spreading across sectors, the same pattern Index Ventures backed in Conduct's round the previous month .

Reed Hastings investing personally, rather than through a fund, removes the diligence layer a venture partnership would normally apply, and increases the share of the round priced on reputation rather than technical benchmarking.

What could happen next?

Risk
OLIX's $3.3bn valuation is being paid before any customer outside the company has benchmarked the DX-1 chip, which does not ship until the second half of 2027.
Meaning
Arm and Hudson River Trading joining from opposite ends of the compute supply chain signals investor confidence that inference demand will outpace training demand.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: Graphcore, the Bristol AI-chip company, raised at a $2.8bn valuation in 2020 on the strength of its architecture before any high-volume customer had shipped product on it; the valuation proved harder to sustain than the funding round, and SoftBank acquired Graphcore in 2024 at a fraction of its peak mark.

Counter-parallel: Arm itself followed the opposite path from Cambridge: it built licensing revenue for over a decade before going public in 2023, by which point its chip architecture was already inside the large majority of the world's mobile devices. Olix is closer to Graphcore's starting position, pre-revenue at scale, than to Arm's.

Consensus view: Arm, the Cambridge chip-design licensor that already earns royalties on the processors most AI accelerators pair with, and Hudson River Trading, a quantitative trading firm that buys compute rather than sells it, both joined Olix's round, a combination that reads as a bet on inference-chip demand from two very different points in the same supply chain.

Counter-view: No published third-party analysis of Olix's technical roadmap turned up in the sources for this briefing. The unattributed risk worth naming: the DX-1 decode accelerator does not reach first customers until the second half of 2027, more than a year after this round closed, so the $3.3bn valuation is being paid for a chip nobody outside the company has yet benchmarked.

Key tension: Whether Olix's board additions, Stanford's Nick McKeown for technical credibility and Wise's former CFO Matt Briers for listing discipline, signal a company preparing to ship on schedule or one preparing for scrutiny it expects before it does.

Sources:OLIX

Mentions:Olix →Arm →Nvidia →CuspAI →London →SoftBank →Sovereign AI Unit →Bristol →Netflix →Cambridge →Index Ventures →

First Reported In

Update #14 · UKRI's sponsor department no longer exists

OLIX· 24 Aug 2026

Read original →

Different Perspectives

Nscale and Open Cosmos

Nscale chose the New York Stock Exchange for its listing on 18 September, putting Britain's largest AI infrastructure bet to American public investors rather than British ones. Open Cosmos took the opposite route four days earlier, raising nine figures from an all-domestic syndicate on five years of profit, evidence that staying is possible when the balance sheet allows it.

Dame Chi Onwurah and the Science, Innovation and Technology Committee

Committee chair Dame Chi Onwurah wrote to government on 7 September asking how Matt Clifford's conflict at ARIA arose and what safeguards protect its governance, and expects a detailed response. Her question has not yet been put to the Sovereign AI Unit, whose own chair sits at a venture capital firm while overseeing state AI equity.

The Entrepreneurs Network

The Entrepreneurs Network's founder survey found 65% say Britain is easy to start a business in but only 14% say it is easy to scale one, with 82% negative on tax and 74% finding investment hard to access. On this reading the constraint is regulation and tax, not the capital-vehicle design the state keeps adjusting.

New Economics Foundation

The New Economics Foundation argues fiscal accounting rules, not political will, cap what Britain's state capital vehicles can do. Matching the KfW and Bpifrance benchmark of 1% of GDP would need the National Wealth Fund to deploy roughly GBP21bn a year by 2028-29, about four times its current capacity.

Competition and Markets Authority

The CMA's 8 September report on public procurement asked whether Britain's roughly GBP400bn state-spending system is built to grow high-potential firms rather than simply widen SME participation. Its Recommendation 5 calls for a dedicated frontier-technology procurement framework, an official acknowledgement that today's design may serve the wrong target.

Highland Europe

Highland Europe, the growth-equity firm behind a €1bn-plus fund, took €65m from the British Business Bank into its Technology Growth Fund VI on 30 July via British Patient Capital. For a Geneva-based growth investor, the Bank's cheque is routine cornerstone capital, unrelated to which Whitehall department currently claims to sponsor UKRI.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.